This is a summary of a clinical study called CARTITUDE-1. This study tested the anti-cancer chimeric antigen receptor-T cell (CAR-T ) therapy ciltacabtagene autoleucel, abbreviated as cilta-cel, in people with multiple myeloma, a cancer that affects a specific type of blood cell called plasma cells. The participants in this study had relapsed or refractory disease, which means that their cancer did not improve or returned after 3 or more previous anti-cancer treatments.This is a Plain Language Summary of Publication article from Future Oncology which looks at a treatment option for people with relapsed or refractory multiple myeloma.  This means that their cancer does not improve or has returned after 3 or more previous anti-cancer treatments. This study, called CARTITUDE-1, tested a therapy called anti-cancer chimeric antigen receptor-T cell (CAR-T) therapy ciltacabtagene autoleucel ( cilta-cel) for the treatment of people with relapsed or refractory multiple myeloma.

Read the full article here.

The original article on which this summary is based on is titled ‘Ciltacabtagene autoleucel, a B-cell maturation antigen-direct chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study’. The article was published in The Lancet. 

You can read the original article here.